Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
Clinical trial NCT03821935 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03821935
- Sponsor
- AbbVie
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-21
- Primary completion
- 2027-06-01
- Enrollment
- 364
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.